Condition

Recurrent Glioblastoma, IDH-Wildtype clinical trials and research

• 11Clinical trials
• 2Countries

Newest Recurrent Glioblastoma, IDH-Wildtype clinical trials

All recruiting trials (11)

• "177Lu" Lu-DOTA-EB-RGD2 Therapy for Recurrent High-Grade Glioma

  This study tests a radiopharmaceutical called Lu-177 DOTA-EB-RGD2 to see if it is safe and tolerable in adults with recurrent high-grade gliomas.

  Recruiting at 2 sites Early Phase 1 Beijing Tiantan Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07655869

• Targeted radioligand therapy for recurrent glioblastoma with Lu-177 XT771

  This early-phase study tests whether a radiolabeled medicine (Lu-177 XT771) delivered directly into the tumor cavity is safe and tolerable for adults with recurrent glioblastoma.

  Recruiting at 2 sites Early Phase 1 Beijing Tiantan Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07648823

• Locally delivered EGFR/IL13Rα2 CAR T-cell therapy for recurrent high-grade gliomas

  This phase I study tests whether a patient's own EGFR/IL13Rα2 CAR T cells, given directly into the brain, are safe and can help adults with recurrent or progressive high-grade gliomas.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07544992

• P134 CAR‑T Cell Therapy for Recurrent Glioblastoma

  This study will try P134 CAR‑T cells that target CD44 and CD133 to see if they are safe and can help control tumors in adults with recurrent IDH‑wildtype glioblastoma.

  Recruiting Phase 1/2 Tasly Pharmaceutical Group Co., Ltd · Beijing · NCT07318818

• GI-102 With or Without Pembrolizumab Before Surgery for Recurrent or Progressive Grade 4 Gliomas

  The team will test whether giving GI-102 alone or together with pembrolizumab before surgery helps adults with recurrent or progressive IDH‑wildtype glioblastoma or IDH‑mutant grade 4 astrocytoma.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07301268

• ERAS-801 for operable or recurrent EGFR-altered IDH-wildtype Grade IV glioblastoma or astrocytoma

  This trial tests ERAS-801, a brain-penetrant EGFR blocker, to see if it is safe and changes tumor metabolism in adults with resectable or recurrent IDH-wildtype Grade IV glioblastoma or astrocytoma that have EGFR amplification or mutation.

  Recruiting Phase 1 Jonsson Comprehensive Cancer Center · Los Angeles, California and 1 other locations · NCT07089641

• Adding triapine to radiation therapy for recurrent glioblastoma and astrocytoma

  This early-phase study tests whether giving the drug triapine together with radiation is safe and tolerable for adults whose glioblastoma or astrocytoma has come back.

  Recruiting at 36 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 42 other locations · NCT06860594

• Combination therapy for recurrent glioblastoma after surgery

  This study is testing a new combination treatment for patients with recurrent glioblastoma after surgery to see if it can improve their outcomes.

  Recruiting Phase 1 Duke University · Durham, North Carolina · NCT06455605

• Triapine plus temozolomide for recurrent glioblastoma

  This trial tests whether adding the drug triapine to temozolomide helps people with recurrent IDH‑wildtype glioblastoma.

  Recruiting Phase 1 Northwestern University · Chicago, Illinois · NCT06410248

• Using fat-derived stem cells to treat recurrent brain tumors during surgery

  This study is testing whether injecting fat-derived stem cells directly into the brain during surgery can help people with recurrent brain tumors feel better and live longer.

  Recruiting Phase 1 Mayo Clinic · Jacksonville, Florida · NCT05789394

• Adding selinexor to temozolomide for recurrent glioblastoma.

  This trial tests whether adding selinexor to standard temozolomide helps adults with IDH‑wildtype, MGMT‑methylated glioblastoma that has come back.

  Recruiting at 35 sites Phase 1/2 National Cancer Institute (NCI) · Phoenix, Arizona and 38 other locations · NCT05432804

Related topics

Quick answers

How many Recurrent Glioblastoma, IDH-Wildtype clinical trials are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in United States (8 trials), China (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 6, Phase 1/2: 2, Early Phase 1: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →